
Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.

Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.

Experts at an Institute for Value-Based Medicine event held October 14, 2025, in Aurora, Colorado, explored advances in neurology care, cross-specialty collaboration, and strategies to improve access and therapy.

Experts met in Park City, Utah, on October 7, 2025, to discuss how new technologies can help address chronic kidney disease.

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

Payer and health system leaders convened in Pittsburgh, Pennsylvania, on September 9, 2025, to discuss the interconnected health conditions of cardiovascular-kidney-metabolic (CKM) syndrome.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
